NY Aptiom Team!

Discussion in 'Sunovion' started by Anonymous, Jan 19, 2015 at 6:39 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Lets face it this group has absolutely no advantage and they have been absolutely killing the nation since day 1. What the difference?
     

  2. Anonymous

    Anonymous Guest

    planning, execution, dedication to patients and millions paid to NYU during the clinical trials and hundreds of thousands paid to NYU and Dr. Vazquez since launch (webcasts and programs).

    But mostly it is just the planning and execution and, yes we are better than you.
     
  3. Anonymous

    Anonymous Guest

    Not better just luckier. You all are not better then the lowest producing team just ended up with a better territory. Put you in a low producing territory and you all would be just that; bottom feeders.
     
  4. Anonymous

    Anonymous Guest

    Jealousy at its finest. Go NY!
     
  5. Anonymous

    Anonymous Guest

    NY scripts are. at least, double the next closest region. In many cases, the script total is 4-5 times the other regions. The launch of Aptiom is even more of a disaster without the immense contributions of the New York district.

    The vast majorityof prescriptions come from lower Manhattan.

    Go Big Apple
     
  6. Anonymous

    Anonymous Guest

    It's still not going to help save the product. The Brovana reps picking up Aptiom will not help save the product, either. One thing that may help a little is if managed markets would get off their a$$es and start working and contract at all the plans where Aptiom is ST'd or PA'd when vimpat is unrestricted. There are tons of those plans and we just ignore that fact.

    See you all in the unemployment line right after they realize that monotherapy indication will not change a thing.

    I hear the Brovana reps are pissed that they have to jump in to try and save this dog.
     
  7. Anonymous

    Anonymous Guest

    Its all their manager, just ask him.
     
  8. Anonymous

    Anonymous Guest

    And... queue 2015 when they become last in the nation because their quotas go through the roof. Same thing happened with Latuda.
     
  9. Anonymous

    Anonymous Guest

    Not true, ask Tony in Chicago about how quotas don't go up. Old Sunovion this was true.

    Not in G-Mans world!

    Chuck
     
  10. Anonymous

    Anonymous Guest

    Males on this NY (KY) team are gloryhole gaggers.
    Females on this NY team are dikes on bikes without seats.

    Bunch o assclowns.
     
  11. Anonymous

    Anonymous Guest

    From what we all saw, the NY team did well because Sunovion pumped hundreds of thousands of dollars into NYU prior to approval and during the clinical trials. Post launch Sunovion pumped tens of thousands of dollars into NYU. Blanca Vazques did the launch webcast and then completed 30-40 speaker programs for reps in the Northeast.
     
  12. Anonymous

    Anonymous Guest

    Exactly. Which is the whole point of speaker programs--buy the big boys off to get the business. The professional plate lickers that come to most of the dinner programs will never prescribe much for us, but it keeps money flowing into the hands of opinion leaders. Most of us reps tolerate the bovine fecal matter because we are under the gun to hold speaker programs, and we don't really care who comes (we do, actually, but we don't) in order to fill seats to get the box checked and our manager off our backs. Hey, lots of you are in marketing because you could not cut it in sales. There is a difference, you know. Nothing, and I mean NOTHING (not dinner programs, not focus groups, not the glossy pieces you make) will ever take the place of a good rep that knows how to SELL.
     
  13. Anonymous

    Anonymous Guest

    Management here seems to think that it is 1990. Call metrics, dinner programs, open gallery. Physicians understand what Aptiom is and physicians will not write for it. Epileptologists will use it as a last resort. Speakers will only write for it for the honorarium.

    Pressure the reps, blame the reps. Nothing will change.

    This is a bad product and a flawed launch.
     
  14. Anonymous

    Anonymous Guest

    Wish some of the above posts were true. Fact of the matter is Sunovion spent little on the product pre-launch and most of the studies were done in Europe.

    A key reason NY is doing well... not a controlled substance in a state where that is an auto PA if you are.
     
  15. Anonymous

    Anonymous Guest

    People. People!! Why are we spending any energy or attention on Aptiom? Is there anything else than can be said that speaks more loudly than the actual sales (or pathetic and miserable lack there of) of the product?

    If you are promoting it you know there is no reason to waste your time and energy searching for why NY share and volume is slightly less pathetic than the rest of the country. Let's face it, this drug is dead. Brovana peeps coming over to throw some more share of voice on it is simply pathetic. Like respiratory reps with no relationships with neurologists are going to do a thing to bend the trend line. How stupid are we as an organization. Such a strategy will do nothing to increase aptiom sales and will hinder and reduce brovana share. Brilliant. Simply brilliant.

    Who's bright idea was this. Such a knee jerk not very well thought out strategy has the stink of Sippy all over it. WE SUCK.